Radiopharmaceutical

EQS-News: Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange

Retrieved on: 
Thursday, September 12, 2024
Radiopharmaceutical, AG, USD, Research, University, NHL, Bone marrow, Patient, Annual general meeting, FDA, Supervisory board, Diagnosis, Primary aldosteronism, Cancer, Food, IPO, Hypertension, Frankfurt Stock Exchange, CXCR4, IIS, Regulated market, Radionuclide, AMERICA, Bookrunner, Patent, Pharmaceutical industry

Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange

Key Points: 
  • Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange
    The issuer is solely responsible for the content of this announcement.
  • While Eckert & Ziegler's core business revolves around the production and distribution of radioisotopes, Pentixapharm is dedicated to the development and approval of new radiopharmaceuticals.
  • The planned IPO enables Pentixapharm to target investors specifically interested in the company's innovative and forward-looking pipeline.
  • As an independent company, Pentixapharm can now operate more flexibly to advance its research and development projects.

MTTI Reports on Fast-Acting Sprayable Molecule to Visualize Tumors for Real-Time Fluorescence-Guided Cytoreductive Surgery

Retrieved on: 
Thursday, September 12, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Radiopharmaceutical, Neoplasm, Patient, Fluorescence, Intellectual property, FGS, Tissue, Cell biology, CRS, SingHealth, Weill Cornell Medicine, Conference, Cancer, Abdominal cavity, Progression-free survival, NMRC, Therapy, Surgeon, WMIC, National Cancer Institute, Associate professor, Assistant, Development, SBIR, Brain, MD, NCI

This convenient fast-acting technology* shows promise as an effective real-time tool for oncologists in fluorescence-guided surgery (FGS).

Key Points: 
  • This convenient fast-acting technology* shows promise as an effective real-time tool for oncologists in fluorescence-guided surgery (FGS).
  • This will allow clinicians to see small tumor residue and achieve a more complete resection of cancer in the abdominal cavity.
  • Dr. Johnny Ong, MD, Associate Professor, Department of Sarcoma, Peritoneal and Rare Tumors, National Cancer Centre Singapore** commented: “One of the limitations of cytoreductive surgery (CRS) is the difficulty in distinguishing tumors from normal and scar tissues.
  • *This research is supported by the National Cancer Institute (NCI) for a SBIR phase II grant # R44CA275434 to MTTI.

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

Retrieved on: 
Thursday, September 12, 2024
Radiopharmaceutical, Acute myeloid leukemia, Research, NETS, Patient, FDA, Orano, Cancer, Multiple myeloma, Alpha, Breakthrough therapy, Glomus tumor, PET, RECIST, Lymphoma, TAT, Pharmaceutical industry

AlphaMedixTM is a TAT which consists of a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles.

Key Points: 
  • AlphaMedixTM is a TAT which consists of a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles.
  • “We are excited to develop a leading-edge project in the rapidly evolving field of radioligand therapies in rare cancers.
  • Early results for 212Pb have demonstrated its differentiated biophysical and clinical profile, reinforcing its potential to be a transformative radioligand therapeutic for patients across multiple difficult-to-treat rare cancers.
  • Through focused strategic decisions the company has reshaped and prioritized its pipeline, leveraging its expertise in immunoscience to drive progress.

Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain

Retrieved on: 
Tuesday, September 10, 2024
Curium, Radiopharmaceutical, Patient, FDA, Cancer, Food, INN, Prostate cancer, PET, PSMA, Nuclear medicine, Medical imaging

PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Spain, PYLCLARI® is now available for patients with prostate cancer.

Key Points: 
  • PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Spain, PYLCLARI® is now available for patients with prostate cancer.
  • PYLCLARI® is being produced by Curium at two sites in Madrid and one site in Sevilla, ensuring timely and efficient distribution across the country.
  • In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021.
  • The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

Human medicines European public assessment report (EPAR): Xofigo, radium Ra223 dichloride, Date of authorisation: 13/11/2013, Revision: 15, Status: Authorised

Retrieved on: 
Wednesday, August 28, 2024
Select, Metastasis, Prostate, European Medicines Agency, Injection, Vomiting, International, Neutrophil, Radiation, Diarrhea, Neoplasm, Cancer, Language, Commission, Medical Subject Headings, Medicine, Prednisone, Bone pain, Pain, Prostate cancer, Thrombocytopenia, Calcium, Safety, ATC, Fracture, European Commission, Radiopharmaceutical, Patient, Life, Neutropenia, Risk, Marketing, Male, Prednisolone, Hormone, Alpha, INN, Castration, IIA, Radioactive decay, CHMP, Nausea, Anatomy, Tissue, Medical device

Human medicines European public assessment report (EPAR): Xofigo, radium Ra223 dichloride, Date of authorisation: 13/11/2013, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Xofigo, radium Ra223 dichloride, Date of authorisation: 13/11/2013, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Lymphoseek, tilmanocept, Date of authorisation: 19/11/2014, Revision: 8, Status: Withdrawn (authorisation)

Retrieved on: 
Wednesday, August 28, 2024
Select, Neoplasm, Breast cancer, News, International, Medicine, Melanoma, SRD, Language, Commission, Medical Subject Headings, ATC, European Commission, Radiopharmaceutical, Marketing, Overview, Carcinoma, INN, IIA, Patient, Diagnosis, CHMP, Anatomy

- Application under evaluation - CHMP opinion - European Commission decision Overview The marketing authorisation for Lymphoseek (SRD) has been withdrawn at the request of the marketing-authorisation holder.

Key Points: 
  • - Application under evaluation - CHMP opinion - European Commission decision Overview The marketing authorisation for Lymphoseek (SRD) has been withdrawn at the request of the marketing-authorisation holder.
  • Product information Latest procedure affecting product information: IB/0023/G 10/06/2024 This medicine’s product information is available in all official EU languages.
  • Select 'available languages' to access the language you need.
  • External imaging and intraoperative evaluation may be performed using a gamma detection device.

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Retrieved on: 
Monday, August 26, 2024
ASCO, Cytokine release syndrome, Annual general meeting, B cell, Prognosis, Congress, CD123, Radiopharmaceutical, Nuclear medicine, Neoplasm, Bone marrow, Therapy, DLL3, Alpha particle, Gene family, Carcinoma, AML, Lung cancer, Tumor microenvironment, Clinical trial, Novartis, Molecular Partners, CHF, EANM, Cancer Immunology Research, Partnership, CD70, SNMMI, Tetra, DARPin, Society, Survival, Toxicity, Molecular imaging, Kidney, Radionuclide, Molecule, CD33, RDT, SCLC, Patient, Pharmaceutical industry

53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the first half-year of 2024.

Key Points: 
  • 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the first half-year of 2024.
  • Throughout H1 2024, Molecular Partners has continued to demonstrate the RDT platform's ability to deliver on its intended design.
  • In January 2024, Molecular Partners entered into a strategic collaboration with Orano Med to co-develop 212Pb-based RDTs for patients with solid tumors.
  • In June 2024, Molecular Partners nominated MP0712 as its first RDT candidate, a 212Pb-based DLL3-targeting RDT in its co-development program with Orano Med.

EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden

Retrieved on: 
Wednesday, August 21, 2024
Investment, EUR, Nuclear medicine, Silicon, Saxons, Free, Regional development, City, Radiopharmaceutical, Economy, Transport

In the presence of the Saxon State Ministers Martin Dulig and Thomas Schmidt as well as the Mayor of Dresden Dirk Hilbert, the medical technology company Eckert & Ziegler today inaugurated its new 1,700 square meter facilities in Dresden with around 200 guests.

Key Points: 
  • In the presence of the Saxon State Ministers Martin Dulig and Thomas Schmidt as well as the Mayor of Dresden Dirk Hilbert, the medical technology company Eckert & Ziegler today inaugurated its new 1,700 square meter facilities in Dresden with around 200 guests.
  • Eckert & Ziegler is investing up to € 50 million in the expansion of the production site.
  • We are investing EUR 6.8 million in the expansion of the Dresden-Rossendorf commercial area in order to make such establishments possible.
  • We are happy that an internationally leading company such as Eckert & Ziegler has chosen Dresden as the location for their expansion.

An Asian Company Achieves Breakthrough in the Key Technology of Ac-225 Preparation

Retrieved on: 
Thursday, August 15, 2024
Shenzhen, Nuclear medicine, Isotope, Radiopharmaceutical, Breast cancer, Government, Shenzhen University, Lung cancer, Southwest Medical University, Survival, Royal Academy of Arts, Research, Cancer, Prostate cancer, Imperial College London, Royal Society, Hong Kong Polytechnic University, Tsinghua University, Royal, Chinese Academy of Engineering, Global health, Glomus tumor, Sale, Pharmaceutical industry

This core technology has been rigorously validated by a well-known research university in the UK, marking a significant milestone for PanMediso in the scale-up and commercial production of Ac-225.

Key Points: 
  • This core technology has been rigorously validated by a well-known research university in the UK, marking a significant milestone for PanMediso in the scale-up and commercial production of Ac-225.
  • It not only improves patient survival rates and treatment efficacy while reducing side effects but also lowers medical costs.
  • With the combined efforts of our international team, we will continue to advance nuclear medicine technology."
  • We aim to provide a comprehensive solution from raw materials to finished products, from research to scaling, and to commercial-level production.

EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study

Retrieved on: 
Wednesday, August 14, 2024
PSMA, Radiopharmaceutical, Standard of care, Partnership, CMO, Prostate cancer, GMP

Berlin, August 13, 2024 - Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) today announced the signing of a significant multi-year agreement under which Eckert & Ziegler will serve as the European contract manufacturing organization (CMO) for Telix's ProstACT GLOBAL Phase III study.

Key Points: 
  • Berlin, August 13, 2024 - Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) today announced the signing of a significant multi-year agreement under which Eckert & Ziegler will serve as the European contract manufacturing organization (CMO) for Telix's ProstACT GLOBAL Phase III study.
  • The contract covers the supply of the entire European patient base from the state-of-the-art facility in Berlin.
  • We are convinced that this continued strategic partnership will contribute significantly to the success of our ProstACT GLOBAL study."
  • Eckert & Ziegler operates several CMO sites worldwide and offers a range of other services along the entire value chain.